Tumor Biology

, Volume 37, Issue 3, pp 3059–3069 | Cite as

PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis

Original Article

Abstract

Epithelial ovarian cancer (EOC) is the most lethal of the gynecologic malignancies, mainly due to the advanced stage at diagnosis and development of cisplatin resistance. The sensitivity of tumor cells to cisplatin is frequently affected by defect in DNA mismatch repair (MMR), which repairs mispaired DNA sequences and regulates DNA-damage-induced apoptosis. However, the role of postmeiotic segregation increased 2 (PMS2), a member of MMR protein family, in cisplatin resistance remains elusive. In the present study, we demonstrated the frequent deficiency of PMS2 and phosphorylation of Akt in EOC cell lines and tissues. Results of complex immunoprecipitation (co-IP) and protein stability assay indicated that activated Akt could directly bind to PMS2 and cause degradation of PMS2 in EOC cells. In addition, functional experiments revealed that PMS2 was required for cisplatin-induced apoptosis and cell cycle arrest in G2/M phase. These findings provide a novel insight into molecular mechanisms linking MMR with chemoresistance and suggest that stabilization of PMS2 expression may be useful in overcoming the cisplatin resistance in EOC.

Keywords

EOC Epithelial ovarian cancer PMS2 Postmeiotic segregation increased 2 MMR Mismatch repair Akt Protein kinase B Cisplatin resistant 

Notes

Acknowledgments

Our research was supported by the National Natural Science Foundation of China (Nos. 81072133, 81302265, and 81272860) and Wuhan Science and Technology Bureau (No. 2014060101010042).

Conflicts of interest

All the authors declare no conflicts of interest.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Suryadi J, Bierbach U. DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. Chemistry. 2012;18(41):12926–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7(10):1353–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Kothandapani A, Sawant A, Dangeti VS, Sobol RW, Patrick SM. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013;41(15):7332–43.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of adjuvant 5-fluorouracil therapy for patients with EMAST-positive stage II/III colorectal cancer. PLoS ONE. 2015;10(5):e0127591.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Peltomaki P. Deficient DNA, mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10(7):735–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Drake AC, Campbell H, Porteous ME, Dunlop MG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer. 2003;13(3):262–77.CrossRefPubMedGoogle Scholar
  11. 11.
    Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87. e3.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Peltomaki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 2003;105(5):617–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67(13):6325–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003;98(10):2199–206.CrossRefPubMedGoogle Scholar
  16. 16.
    Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Mol Carcinog 2014Google Scholar
  17. 17.
    Jia J, Zhang Y, Cai J, Wang J, Ding H, Zhou J, et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25(6):1498–504.CrossRefPubMedGoogle Scholar
  18. 18.
    Su CH, Wang CY, Lan KH, Li CP, Chao Y, Lin HC, et al. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal. 2011;23(11):1824–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, et al. Molecular imaging of Akt kinase activity. Nat Med. 2007;13(9):1114–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64(13):4394–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9(1):89–96.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang Y, Shu YM, Wang SF, Da BH, Wang ZH, Li HB. Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3beta is implicated in the treatment of cervical carcinoma. BMC Cancer. 2010;10:58.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Soni A, Bansal A, Singh LC, Mishra AK, Majumdar M, Regina T, et al. Gene expression profile and mutational analysis of DNA mismatch repair genes in carcinoma prostate in Indian population. OMICS. 2011;15(5):319–24.CrossRefPubMedGoogle Scholar
  24. 24.
    Collins SL, Herve R, Keevil CW, Blaydes JP, Webb JS. Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. PLoS ONE. 2011;6(12):e28123.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Prahm KP, Karlsen MA, Hogdall E, Scheller NM, Lundvall L, Nedergaard L, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A. 2003;100(5):2420–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza P, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013;210(3):581–603.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2008;7(18):2846–55.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004;3(8–9):1091–101.CrossRefGoogle Scholar
  32. 32.
    Horibe S, Matsuda A, Tanahashi T, Inoue J, Kawauchi S, Mizuno S, et al. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci. 2015;124:31–40.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jinghui Jia
    • 1
    • 2
  • Zehua Wang
    • 2
  • Jing Cai
    • 2
  • Yuan Zhang
    • 2
  1. 1.Department of Obstetrics and GynecologyAir Force General Hospital, PLABeijingChina
  2. 2.Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations